Surfactant administration in premature infants with RDS
1Neonatal Intensive Care Unit Pediatric Hospital Clinical Centre Sarajevo
DOI: 10.22514/SV21.042007.5 Vol.2,Issue 1,April 2007 pp.21-24
Published: 20 April 2007
Background. The significant advancement in the treatment of respiratory distress syndrome can be attributed to prenatal identification of high risk pregnancies, prevention of illness through antenatal care, prenatal administration of glucocorti-coids, advancement in respiratory support and surfactant therapy. These measures resulted in the reduction of mortality and morbidity rates in preterm infants.
Patients and methods. We analyzed data of 78 preterm babies with respiratory distress syndrome hospitalized in the NICU of the Pediatric Clinic, KCU Sarajevo. All children included in the study were mechanically ventilated and treated with one or more doses of bovine surfactant (Survanta) as rescue therapy. Surfactant was given to children with clinical and radiological
signs of RDS, who required FiO2>0,40. We used the standard procedure of giving surfactant therapy to intubated children in sterile conditions, after we confirmed, by X-ray, correct tube placement.
Results. We investigated the clinical efficacy of surfactant in relation to time of administration, O2 requirement and necessity of one or more doses of surfactant. We found that early treatment with surfactant replacement- within 6 hours of birth- is more effective, and resulted in a significant reduction of mortality rate (p<0,01). Treatment with multiple doses is more effective in comparison to one dose, although there was not a significant difference (p<0,20) between the treated groups. There is a
significant difference (p<0,01) between groups related to O2 requirement. In the group of babies which required 60% or more O2 concentration in inhaled air at the time of surfactant replacement, mortality rate was significantly higher (p<0,01). Conclusion. Our study confirmed the benefits of surfactant therapy in preterm babies with respiratory distress syndrome. We confirmed the advantages of early treatment vs. late treatment, but we could not confirm the obvious advantage of multiple over single doses. So, a reasonable recommendation is to treat the infants as soon as clinical signs of developing respira-tory distress appear with an individual dose for each infant.
respiratory distress syn-drome, surfactant, preterm
ISMETA KALKAN,SUADA HELJIĆ ,AMRA ČENGIĆ,VERICA MIŠANOVIĆ,DUŠKO ANIĆ,FEDŽAT JONUZI,HAJRIJA MAKSIĆ. Surfactant administration in premature infants with RDS. Signa Vitae. 2007. 2(1);21-24.
1. Jobe AH. Lung Development. In: Martin RJ, Fanaroff AA, eds. Neonatal-perinatal Medicine, Diseases of the Fetus and Infant. St Louis: Mosby; 1997, pp 1019–1040.
2. Honrubia D, Stark AR. Respiratory Disorders. In: Cloherty JP, Eichenwald EC, Strak AR, eds. Manuale of Neonatal Care. Philadelphia: Lippincott, Williams&Wilkins; 1997, pp 341-378.
3. Gomella TL, Gleason BL. Hyalin Membrane Disease. In: Gomella TL, eds. Neonatology. Appleton and Lange; 1988/89, pp 381-385.
4. Katz R. Function and Physiology of the Respiratory System. In: Furhman BP, Zimmerman JJ, eds. Pediatric critical care. St Louis: Mosby; 1992, pp 386–399.
5. Fackler JC, Arnold JH, Nickols DG, Rogers MC. Acute Respiratory Distress Syndrome. In: Rogers MC, eds. Textbook of Pediatric Intensive Care, Baltimore: Williams and Wilkins; 1996, pp 197-225.
6. Leahy A. Respiratory distress. In: Southall D, Coulter B, Ronald Ch, Nicholson S, Parke S, eds. International Child Health Care. London: BMJ; 2002, pp 129-131.
7. Jobe AH. Pulmonary surfactant therapy. New England Journal of Medicine 1993; 328:861-8.
Science Citation Index Expanded (SciSearch) The Science Citation Index (SCI) is a citation index originally produced by the Institute for Scientific Information (ISI) and created by Eugene Garfield. It (Science Citation Index Expanded) covers more than 8,500 notable and significant journals, across 150 disciplines in science and technology, from 1900 to the present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.
IndexCopernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.
Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.
Scopus Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.
Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.